Skip to main content
Triangle logo TriangleGet started

Adagrasib (NCT07288034)

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial: a one-minute explainerNCT072880341 min

Adagrasib trial for Lung Non-Small Cell Carcinoma (NCT07288034). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with stage IIIB or IV non-small-cell lung cancer without sensitizing EGFR, ALK or ROS1 alterations. Patients start PD-1/PD-L1 treatment, with or without chemotherapy; up to four cycles are allowed.

The idea: use blood tumor DNA to guide treatment duration. Checkpoint therapy aims to restore immune attack. Patients with eligible disease control are randomized to stop or continue treatment. After progression, mutations guide combinations. Future groups remain undefined. Blood and molecular testing are required.

This phase 2 study plans 535 patients. City of Hope sponsors 13 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.